艾美疫苗子公司无血清狂犬疫苗III期临床试验成功
3月12日，艾美疫苗（06660）发布公告，宣布其全资子公司艾美荣誉（宁波）生物制药有限公司已完成无血清迭代狂犬疫苗的III期临床试验，并获得相应的生产许可证。该疫苗将提交药品上市注册，标志着公司在狂犬疫苗领域取得了重大技术突破，预计将成为全球首款获批上市的无血清狂犬疫苗。
根据已完成的III期临床研究结果，该疫苗显示出良好的安全性、免疫原性和免疫持久性，已全面达到临床试验的预设评价标准。目前全球尚无无血清狂犬疫苗上市，市场主要销售的产品为有血清狂犬疫苗。
公司研发的无血清迭代狂犬疫苗不含动物血清，显著提高了安全性，降低了不良反应的发生概率。根据灼识咨询的统计，预计到2030年，中国狂犬疫苗市场将达到148亿元，公司的产品有望成为疫苗接种机构的首选。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10